Friday, October 10, 2014

Breast Cancer Awareness Month

Did you know that 1 in 8 women will be diagnosed with breast cancer in their lifetime? In 2014 it is estimated that over 232,000 women in the United States will be diagnosed with invasive breast cancer and nearly 40,000 will die as a result of breast cancer. It is the most commonly diagnosed cancer in women worldwide, and the second leading cause of death for women in the U.S. However, it is also important to note that more than 2.8 million women in the U.S. with a history of breast cancer were alive in 2014.1

These numbers illustrate the importance of early detection and screening for the best outcomes. Conducting regular self breast exams and following other screening guidelines for detecting early stage breast cancer are critically important. The American Cancer Society recommends that women receive an annual mammogram beginning at age 40 and are screened regularly. Early detection by mammography also leads to a greater range of treatment options, including less-extensive surgery, the use of chemotherapy with fewer side effects, or even possibly the option to forgo chemotherapy.

These numbers also illustrate the importance of clinical research. Participation in clinical trials provides essential information about the effectiveness and risks of a new treatment. And for breast cancer – like so many other diseases – continued research to discover new and more effective treatments could someday save lives, or even lead to a cure.

You can find more 2014 Breast Cancer Statistics here. If you would like to learn more about clinical trials for breast cancer, you can visit or the American Cancer Society Clinical Trials Matching Service. The National Institutes of Health also features clinical trials, and there are many additional resources, such as to help you find a trial that may be right for you. To learn more about currently enrolling trials at PMG Research, visit us here.


Below: The PMG Research of Raleigh team wearing their pink for Breast Cancer Awareness!

No comments :

Post a Comment

Subscribe Via Email